198 related articles for article (PubMed ID: 36703130)
1. β-catenin-IRP2-primed iron availability to mitochondrial metabolism is druggable for active β-catenin-mediated cancer.
Wu Y; Yang S; Han L; Shang K; Zhang B; Gai X; Deng W; Liu F; Zhang H
J Transl Med; 2023 Jan; 21(1):50. PubMed ID: 36703130
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide inhibits the degradation of IRP2.
Wang J; Chen G; Pantopoulos K
Mol Cell Biol; 2005 Feb; 25(4):1347-53. PubMed ID: 15684386
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutations are associated with increased iron regulatory protein-2 expression in colorectal tumorigenesis.
Horniblow RD; Bedford M; Hollingworth R; Evans S; Sutton E; Lal N; Beggs A; Iqbal TH; Tselepis C
Cancer Sci; 2017 Jun; 108(6):1135-1143. PubMed ID: 28281325
[TBL] [Abstract][Full Text] [Related]
4. Changed iron regulation in scrapie-infected neuroblastoma cells.
Fernaeus S; Hälldin J; Bedecs K; Land T
Brain Res Mol Brain Res; 2005 Feb; 133(2):266-73. PubMed ID: 15710243
[TBL] [Abstract][Full Text] [Related]
5. IRP2 regulates breast tumor growth.
Wang W; Deng Z; Hatcher H; Miller LD; Di X; Tesfay L; Sui G; D'Agostino RB; Torti FM; Torti SV
Cancer Res; 2014 Jan; 74(2):497-507. PubMed ID: 24285726
[TBL] [Abstract][Full Text] [Related]
6. Tempol-mediated activation of latent iron regulatory protein activity prevents symptoms of neurodegenerative disease in IRP2 knockout mice.
Ghosh MC; Tong WH; Zhang D; Ollivierre-Wilson H; Singh A; Krishna MC; Mitchell JB; Rouault TA
Proc Natl Acad Sci U S A; 2008 Aug; 105(33):12028-33. PubMed ID: 18685102
[TBL] [Abstract][Full Text] [Related]
7. Perturbation of Iron Metabolism by Cisplatin through Inhibition of Iron Regulatory Protein 2.
Miyazawa M; Bogdan AR; Tsuji Y
Cell Chem Biol; 2019 Jan; 26(1):85-97.e4. PubMed ID: 30449675
[TBL] [Abstract][Full Text] [Related]
8. Abnormal brain iron metabolism in Irp2 deficient mice is associated with mild neurological and behavioral impairments.
Zumbrennen-Bullough KB; Becker L; Garrett L; Hölter SM; Calzada-Wack J; Mossbrugger I; Quintanilla-Fend L; Racz I; Rathkolb B; Klopstock T; Wurst W; Zimmer A; Wolf E; Fuchs H; Gailus-Durner V; de Angelis MH; Romney SJ; Leibold EA
PLoS One; 2014; 9(6):e98072. PubMed ID: 24896637
[TBL] [Abstract][Full Text] [Related]
9. KLF14 regulates the growth of hepatocellular carcinoma cells via its modulation of iron homeostasis through the repression of iron-responsive element-binding protein 2.
Zhou H; Chen J; Fan M; Cai H; Dong Y; Qiu Y; Zhuang Q; Lei Z; Li M; Ding X; Yan P; Lin A; Zheng S; Yan Q
J Exp Clin Cancer Res; 2023 Jan; 42(1):5. PubMed ID: 36600258
[TBL] [Abstract][Full Text] [Related]
10. Irp2 regulates insulin production through iron-mediated Cdkal1-catalyzed tRNA modification.
Santos MCFD; Anderson CP; Neschen S; Zumbrennen-Bullough KB; Romney SJ; Kahle-Stephan M; Rathkolb B; Gailus-Durner V; Fuchs H; Wolf E; Rozman J; de Angelis MH; Cai WM; Rajan M; Hu J; Dedon PC; Leibold EA
Nat Commun; 2020 Jan; 11(1):296. PubMed ID: 31941883
[TBL] [Abstract][Full Text] [Related]
11. Iron Regulatory Protein 2 Exerts its Oncogenic Activities by Suppressing TAp63 Expression.
Zhang Y; Feng X; Zhang J; Chen X
Mol Cancer Res; 2020 Jul; 18(7):1039-1049. PubMed ID: 32276991
[TBL] [Abstract][Full Text] [Related]
12. Iron regulatory protein 2 turnover through a nonproteasomal pathway.
Chang AH; Jeong J; Levine RL
J Biol Chem; 2011 Jul; 286(27):23698-707. PubMed ID: 21558272
[TBL] [Abstract][Full Text] [Related]
13. Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Song S; Christova T; Perusini S; Alizadeh S; Bao RY; Miller BW; Hurren R; Jitkova Y; Gronda M; Isaac M; Joseph B; Subramaniam R; Aman A; Chau A; Hogge DE; Weir SJ; Kasper J; Schimmer AD; Al-awar R; Wrana JL; Attisano L
Cancer Res; 2011 Dec; 71(24):7628-39. PubMed ID: 22009536
[TBL] [Abstract][Full Text] [Related]
14. A role for lysosomes in the turnover of human iron regulatory protein 2.
Dycke C; Charbonnier P; Pantopoulos K; Moulis JM
Int J Biochem Cell Biol; 2008; 40(12):2826-32. PubMed ID: 18582596
[TBL] [Abstract][Full Text] [Related]
15. FDXR regulates TP73 tumor suppressor via IRP2 to modulate aging and tumor suppression.
Zhang J; Kong X; Zhang Y; Sun W; Wang J; Chen M; Chen X
J Pathol; 2020 Jul; 251(3):284-296. PubMed ID: 32304229
[TBL] [Abstract][Full Text] [Related]
16. Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2).
Galy B; Ferring D; Minana B; Bell O; Janser HG; Muckenthaler M; Schümann K; Hentze MW
Blood; 2005 Oct; 106(7):2580-9. PubMed ID: 15956281
[TBL] [Abstract][Full Text] [Related]
17. Iron-mediated degradation of IRP2, an unexpected pathway involving a 2-oxoglutarate-dependent oxygenase activity.
Wang J; Chen G; Muckenthaler M; Galy B; Hentze MW; Pantopoulos K
Mol Cell Biol; 2004 Feb; 24(3):954-65. PubMed ID: 14729944
[TBL] [Abstract][Full Text] [Related]
18. Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy.
Sandoval-Acuña C; Torrealba N; Tomkova V; Jadhav SB; Blazkova K; Merta L; Lettlova S; Adamcová MK; Rosel D; Brábek J; Neuzil J; Stursa J; Werner L; Truksa J
Cancer Res; 2021 May; 81(9):2289-2303. PubMed ID: 33685989
[TBL] [Abstract][Full Text] [Related]
19. Iron regulatory protein 1 outcompetes iron regulatory protein 2 in regulating cellular iron homeostasis in response to nitric oxide.
Styś A; Galy B; Starzyński RR; Smuda E; Drapier JC; Lipiński P; Bouton C
J Biol Chem; 2011 Jul; 286(26):22846-54. PubMed ID: 21566147
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer.
Coombs GS; Schmitt AA; Canning CA; Alok A; Low IC; Banerjee N; Kaur S; Utomo V; Jones CM; Pervaiz S; Toone EJ; Virshup DM
Oncogene; 2012 Jan; 31(2):213-25. PubMed ID: 21666721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
